PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 11814651-5 2002 At 30 min, JL 13 like clozapine, increased prolactin concentration only at the higher dose (30 mg/kg) while haloperidol at both tested doses induced a dramatic increase of prolactin concentration. Haloperidol 108-119 prolactin Rattus norvegicus 172-181 21533991-7 2011 Both compounds show a non-significant trend towards reversal of the increased secretion caused by dopamine depletion, whereas the D2 receptor antagonist haloperidol further increased prolactin secretion. Haloperidol 153-164 prolactin Rattus norvegicus 183-192 17850459-3 2007 Whereas a parity-induced reduction in haloperidol-stimulated prolactin secretion is evident in ovariectomised rats, it is unknown whether a similar attenuation of prolactin secretion is present in reproductively experienced, cycling pro-oestrous rats. Haloperidol 38-49 prolactin Rattus norvegicus 61-70 17850459-7 2007 In addition, haloperidol-stimulated prolactin secretion was reduced in ovariectomised, reproductively experienced females. Haloperidol 13-24 prolactin Rattus norvegicus 36-45 16528922-2 2006 Experimental studies on rats show that haloperidol, at female, causes: decreasing of the ovarian weight, inhibition of the ovulation, producing a state of distrust and stimulation of lobuloalveolar development of the mammary glands and increasing of serum prolactin levels in both male and female rats. Haloperidol 39-50 prolactin Rattus norvegicus 256-265 15063010-9 2004 Administration of haloperidol produced a marked increase in plasma prolactin levels as compared with the non-lactating controls. Haloperidol 18-29 prolactin Rattus norvegicus 67-76 11814651-6 2002 At 150 min after injection, only haloperidol (0.3 mg/kg) significantly increased serum prolactin level. Haloperidol 33-44 prolactin Rattus norvegicus 87-96 11887930-4 2001 Treatment with haloperidol increased circulating PRL levels 8-fold and tyrosine hydroxylase activity in the stalk-median eminence 1.8-fold. Haloperidol 15-26 prolactin Rattus norvegicus 49-52 11164823-6 2001 The third group of rats received haloperidol (high PRL) and were deprived of pups. Haloperidol 33-44 prolactin Rattus norvegicus 51-54 10700558-2 2000 Systemic administration of the DA receptor antagonist haloperidol caused a sustained (up to 12 h) increase in plasma prolactin concentrations that was accompanied by a transient increase (at 3 h) in the percentage of tyrosine hydroxylase (TH)-immunoreactive (IR) neurons containing FRA-IR nuclei in the DM-ARC. Haloperidol 54-65 prolactin Rattus norvegicus 117-126 10838120-3 2000 In addition, two blood collection procedures were evaluated for their utility in detecting HAL-induced increases in serum prolactin (PRL) levels (i.e., the stress associated with each procedure). Haloperidol 91-94 prolactin Rattus norvegicus 122-131 10838120-3 2000 In addition, two blood collection procedures were evaluated for their utility in detecting HAL-induced increases in serum prolactin (PRL) levels (i.e., the stress associated with each procedure). Haloperidol 91-94 prolactin Rattus norvegicus 133-136 10838120-4 2000 In the in vivo female battery, both HAL and RES increased serum PRL concentrations as expected, although the increase caused by RES was marginal. Haloperidol 36-39 prolactin Rattus norvegicus 64-67 10838120-7 2000 In the in vivo male battery, HAL increased serum PRL concentrations as expected. Haloperidol 29-32 prolactin Rattus norvegicus 49-52 10838120-11 2000 As a result of the higher basal PRL levels, the HAL-induced increase in serum PRL concentrations was completely attenuated in the tail-vein bled animals (1.3-fold). Haloperidol 48-51 prolactin Rattus norvegicus 32-35 10838120-11 2000 As a result of the higher basal PRL levels, the HAL-induced increase in serum PRL concentrations was completely attenuated in the tail-vein bled animals (1.3-fold). Haloperidol 48-51 prolactin Rattus norvegicus 78-81 10838120-12 2000 In contrast, HAL produced a fivefold increase in serum PRL in animals where blood was collected under CO(2) anesthesia at euthanization. Haloperidol 13-16 prolactin Rattus norvegicus 55-58 10838120-14 2000 In summary, HAL-like compounds would be identified in the Tier I male and female battery primarily via increased serum PRL concentrations. Haloperidol 12-15 prolactin Rattus norvegicus 119-122 10700558-6 2000 Co-administration of prolactin antisera (PRL-AB) blocked haloperidol-induced increases in both plasma prolactin concentrations and the percentage of TH-IR neurons expressing FRA in the DM-ARC, but had no effect on haloperidol-induced inhibition of FRA expression in TH-IR neurons in the VL-ARC. Haloperidol 57-68 prolactin Rattus norvegicus 21-30 10700558-6 2000 Co-administration of prolactin antisera (PRL-AB) blocked haloperidol-induced increases in both plasma prolactin concentrations and the percentage of TH-IR neurons expressing FRA in the DM-ARC, but had no effect on haloperidol-induced inhibition of FRA expression in TH-IR neurons in the VL-ARC. Haloperidol 57-68 prolactin Rattus norvegicus 102-111 10700558-8 2000 administration of prolactin also increased the percentage of TH-IR neurons containing FRA-IR nuclei in the DM-ARC, but this effect was of longer duration (up to 6 h) than that of haloperidol in all but the most caudal portion of the DM-ARC. Haloperidol 179-190 prolactin Rattus norvegicus 18-27 10530797-6 1999 Both antipsychotics inhibited prolactin secretion, clozapine at doses starting from 10(-6) M and fluphenazine from 10(-7) M. Haloperidol reversed clozapine-induced prolactin inhibition but left fluphenazine-induced inhibition unchanged. Haloperidol 125-136 prolactin Rattus norvegicus 30-39 10530797-6 1999 Both antipsychotics inhibited prolactin secretion, clozapine at doses starting from 10(-6) M and fluphenazine from 10(-7) M. Haloperidol reversed clozapine-induced prolactin inhibition but left fluphenazine-induced inhibition unchanged. Haloperidol 125-136 prolactin Rattus norvegicus 164-173 9582438-0 1998 Differential effects on D2 dopamine receptor and prolactin gene expression by haloperidol and aripiprazole in the rat pituitary. Haloperidol 78-89 prolactin Rattus norvegicus 49-58 9582438-2 1998 Haloperidol treatment increased the [3H]spiperone-binding by 28%, the levels of D2L and D2S receptor mRNA by 41% and 38%, respectively, and the level of prolactin mRNA by 26%. Haloperidol 0-11 prolactin Rattus norvegicus 153-162 9173349-5 1997 Administration of haloperidol, an inhibitor of dopamine D2 receptors, to pregnant female increased the level of prolactin in fetus plasma from day 20 and diminished its content in the pituitary gland from day 22. Haloperidol 18-29 prolactin Rattus norvegicus 112-121 9521094-11 1998 Nine months of HAL-induced hyperprolactinemia followed by implantation of PRL-producing MMQ cells, which resulted in very high levels of PRL, did not increase TH activity in the stalk-median eminence. Haloperidol 15-18 prolactin Rattus norvegicus 137-140 9387851-0 1997 Reproductive experience reduces haloperidol-induced prolactin secretion in female rats. Haloperidol 32-43 prolactin Rattus norvegicus 52-61 9387851-4 1997 Whereas HAL stimulated increases in plasma PRL concentrations in both nulliparous and primiparous animals, significantly higher levels of plasma PRL were present after both doses of HAL in the nulliparous rats. Haloperidol 8-11 prolactin Rattus norvegicus 43-46 9387851-4 1997 Whereas HAL stimulated increases in plasma PRL concentrations in both nulliparous and primiparous animals, significantly higher levels of plasma PRL were present after both doses of HAL in the nulliparous rats. Haloperidol 182-185 prolactin Rattus norvegicus 145-148 9387851-5 1997 A second experiment investigated the role of lactation in this change in the ability of HAL to stimulate increases in circulating PRL levels. Haloperidol 88-91 prolactin Rattus norvegicus 130-133 9387851-8 1997 The PRL responses in the two groups were identical at the low HAL dose and similar after the high HAL dose. Haloperidol 62-65 prolactin Rattus norvegicus 4-7 9387851-9 1997 These findings demonstrate that a single prior pregnancy and lactation, but not pregnancy alone, significantly reduce the ability of HAL to elevate circulating plasma PRL concentrations. Haloperidol 133-136 prolactin Rattus norvegicus 167-170 9475081-2 1997 Chronic administration of haloperidol (0.2 mg/kg/day/sc for 21 days) caused significant increase in brain DA and serum prolactin. Haloperidol 26-37 prolactin Rattus norvegicus 119-128 9173350-8 1997 This provided evidence that in nonoperated fetuses, it is pituitary prolactin which is secreted in response to haloperidol, while the secretion of nonpituitary prolactin is not controlled by dopamine. Haloperidol 111-122 prolactin Rattus norvegicus 68-77 9292204-1 1997 The main objective of this study was to further elucidate the functional relationship between endogenous dopamine and the prolactin (PRL)-releasing effect of the dopamine antagonists domperidone and haloperidol. Haloperidol 199-210 prolactin Rattus norvegicus 122-131 9292204-1 1997 The main objective of this study was to further elucidate the functional relationship between endogenous dopamine and the prolactin (PRL)-releasing effect of the dopamine antagonists domperidone and haloperidol. Haloperidol 199-210 prolactin Rattus norvegicus 133-136 9292204-5 1997 was followed by an increased plasma PRL concentration in the sham-operated animals; however, in the MBH-lesioned rats where the basal PRL levels were high haloperidol failed to produce additional PRL release. Haloperidol 155-166 prolactin Rattus norvegicus 134-137 9292204-5 1997 was followed by an increased plasma PRL concentration in the sham-operated animals; however, in the MBH-lesioned rats where the basal PRL levels were high haloperidol failed to produce additional PRL release. Haloperidol 155-166 prolactin Rattus norvegicus 134-137 8736437-8 1996 By maintaining high levels of circulating PRL with haloperidol-treatment, we observed a number of colocalizations close to that observed in freely nursing lactating females. Haloperidol 51-62 prolactin Rattus norvegicus 42-45 7518029-2 1994 In the pituitary, haloperidol and sulpiride induced similar increases of mRNAs of pro-opiomelanocortin (POMC) (+65% and +73%), prolactin (PRL) (+821% and +840%) and growth hormone (GH) (+32% and +47%), but sulpiride induced a greater increase of D2R mRNA (+125%) than haloperidol (+92%). Haloperidol 18-29 prolactin Rattus norvegicus 127-136 8613910-2 1996 In in vitro experiments on the isolated anterior pituitary, the spontaneous PRL release was decreased by talipexole, a dopamine D2 receptor full agonist, in a dose-dependent manner to 36% of the basal release, and the decrease was antagonized by haloperidol, a D2 receptor antagonist. Haloperidol 246-257 prolactin Rattus norvegicus 76-79 8613910-4 1996 The decrease in PRL release induced by OPC-14597 was completely antagonized by haloperidol. Haloperidol 79-90 prolactin Rattus norvegicus 16-19 8613910-6 1996 In in vivo experiments, haloperidol increased the serum PRL levels to 8 times the basal PRL level, whereas talipexole decreased the levels to 49% of the basal level. Haloperidol 24-35 prolactin Rattus norvegicus 56-59 21554629-9 1992 In the anterior pituitary gland of estrogen-treated rats, bromocriptine increased and haloperidol decreased both galanin and prolactin levels. Haloperidol 86-97 prolactin Rattus norvegicus 125-134 8204196-5 1994 The ETOH-treated castrated rats showed a significant rise in circulating PRL after injection of the DA receptor antagonist haloperidol metabolite II (HAL), but the administration of the DA receptor agonist R(-)-apomorphine HCL (APO) caused plasma PRL to decline to near undetectable levels. Haloperidol 123-134 prolactin Rattus norvegicus 73-76 8237422-6 1993 Pretreatment of non-lactating rats with haloperidol (which increases plasma prolactin levels) enhanced the gastric contractile response to 5-HT (P < 0.05). Haloperidol 40-51 prolactin Rattus norvegicus 76-85 1380082-4 1992 dosing, risperidone was 3 to 5 times more potent than the classical D2 receptor antagonist haloperidol in stimulating rat prolactin levels in vivo. Haloperidol 91-102 prolactin Rattus norvegicus 122-131 1380082-10 1992 S-9 treatment abolished haloperidol"s effects on pituitary cell prolactin release. Haloperidol 24-35 prolactin Rattus norvegicus 64-73 19912871-7 1992 Chronic haloperidol treatment which induced high levels of circulating prolactin increased the amounts of pre-proNPY mRNA by 70 and 66% in intact and hypophysectomized animals, respectively. Haloperidol 8-19 prolactin Rattus norvegicus 71-80 1703487-8 1991 Chronic treatment with haloperidol, a DA antagonist, increased circulating levels of endogenous rPRL and increased TH activity in the SME to values similar to those after oPRL treatment. Haloperidol 23-34 prolactin Rattus norvegicus 96-100 1786530-7 1991 The PRL response to 0.5 mg/kg haloperidol was higher in ADX lactating animals than that in the controls. Haloperidol 30-41 prolactin Rattus norvegicus 4-7 1786530-8 1991 Morphine given 2 h after haloperidol treatment resulted in a further increase of plasma PRL in ADX, but not in the sham-operated lactating animals. Haloperidol 25-36 prolactin Rattus norvegicus 88-91 1836253-5 1991 Prolactin mRNA content was increased by the third day of haloperidol treatment. Haloperidol 57-68 prolactin Rattus norvegicus 0-9 1350068-5 1992 In the saline-treated animals, administration of nicotine, morphine, 8-OH-DPAT and haloperidol resulted in significant increases in plasma prolactin levels. Haloperidol 83-94 prolactin Rattus norvegicus 139-148 1350068-9 1992 Bromocriptine blocked the prolactin secretion induced by haloperidol as well as by each of the above agonists. Haloperidol 57-68 prolactin Rattus norvegicus 26-35 1310283-0 1992 Indirect evidence to suggest that prolactin mediates the adrenal action of haloperidol to stimulate aldosterone and corticosterone secretion in rats. Haloperidol 75-86 prolactin Rattus norvegicus 34-43 1571479-3 1992 Groups of virgin female DBA/1 mice were subjected to different short-term treatment protocols (5-10 days) with rat PRL and the drugs bromocriptine (inhibits prolactin secretion) and haloperidol (enhances prolactin secretion). Haloperidol 182-193 prolactin Rattus norvegicus 204-213 1625521-2 1992 Young female rats showed a dose-dependent increase in serum and CSF PRL in response to haloperidol. Haloperidol 87-98 prolactin Rattus norvegicus 68-71 19215533-9 1991 The concomitant administration of 17ss-estradiol and haloperidol resulted in a 50% increase in PRL mRNA levels compared to those measured in animals treated with haloperidol alone. Haloperidol 53-64 prolactin Rattus norvegicus 95-98 19215533-9 1991 The concomitant administration of 17ss-estradiol and haloperidol resulted in a 50% increase in PRL mRNA levels compared to those measured in animals treated with haloperidol alone. Haloperidol 162-173 prolactin Rattus norvegicus 95-98 1673267-8 1991 TSH suppression was partially reversed by immunoneutralization with somatostatin antibody, and PRL suppression was completely prevented by a dopamine antagonist (haloperidol). Haloperidol 162-173 prolactin Rattus norvegicus 95-98 1678894-4 1991 In addition, both CBD and haloperidol reduced the occurrence of stereotyped biting induced by apomorphine (6.4 mg/kg), increased plasma prolactin levels and produced palpebral ptosis, as compared to control solutions. Haloperidol 26-37 prolactin Rattus norvegicus 136-145 1943474-0 1991 Enhanced haloperidol-induced prolactin stimulation with chronic neuroleptic treatment in the rat. Haloperidol 9-20 prolactin Rattus norvegicus 29-38 1943474-1 1991 Animals were treated either acutely, or chronically for 21 days, with a low dose (0.1 mg/kg) of haloperidol, then sacrificed to obtain trunk blood for radioimmunoassay of prolactin (PRL) level. Haloperidol 96-107 prolactin Rattus norvegicus 171-180 1943474-1 1991 Animals were treated either acutely, or chronically for 21 days, with a low dose (0.1 mg/kg) of haloperidol, then sacrificed to obtain trunk blood for radioimmunoassay of prolactin (PRL) level. Haloperidol 96-107 prolactin Rattus norvegicus 182-185 2495929-10 1989 Haloperidol induced a dramatic 30- to 40-fold increase in plasma PRL in intact rats. Haloperidol 0-11 prolactin Rattus norvegicus 65-68 11175438-5 1990 lowered, whereas haloperidol (0.025 mg/kg, s.c.) increased serum prolactin levels. Haloperidol 17-28 prolactin Rattus norvegicus 65-74 2114005-0 1990 Alterations in prolactin secretion during the 1st postnatal month following perinatal dopaminergic blockade with haloperidol. Haloperidol 113-124 prolactin Rattus norvegicus 15-24 2114005-1 1990 This research was intended to study the effects of perinatal haloperidol administration on the postnatal secretion of prolactin (PRL) with the aim of investigating the existence of a "critical period" during which the lack of dopamine influence could cause long-term alterations in the secretion of this hormone. Haloperidol 61-72 prolactin Rattus norvegicus 118-127 2114005-1 1990 This research was intended to study the effects of perinatal haloperidol administration on the postnatal secretion of prolactin (PRL) with the aim of investigating the existence of a "critical period" during which the lack of dopamine influence could cause long-term alterations in the secretion of this hormone. Haloperidol 61-72 prolactin Rattus norvegicus 129-132 2114005-7 1990 These data confirm the existence of a "critical period" during which perinatal administration of haloperidol alters the postnatal PRL production and secretion patterns. Haloperidol 97-108 prolactin Rattus norvegicus 130-133 2495929-11 1989 Haloperidol induced a 3-fold rise in plasma PRL on day 1 after SS and a transient 2.5-fold rise on day 2. Haloperidol 0-11 prolactin Rattus norvegicus 44-47 3029529-6 1987 However, after stimulation of prolactin secretion through blockade of the dopaminergic neurotransmission with haloperidol (0.1 mg/kg), both THIP (10 mg/kg) and SL 76002 (200 mg/kg) significantly counteracted the neuroleptic-induced prolactin rise with a potency which is in line with their ability to inhibit 3H-GABA binding in the anterior pituitary. Haloperidol 110-121 prolactin Rattus norvegicus 30-39 3264239-5 1988 Haloperidol, a DA antagonist, induced a 20-fold rise in PRL before the surge, a 2-fold rise above peak PRL levels at 1500 h, and a 50-fold rise on the morning of day 31. Haloperidol 0-11 prolactin Rattus norvegicus 56-59 3264239-5 1988 Haloperidol, a DA antagonist, induced a 20-fold rise in PRL before the surge, a 2-fold rise above peak PRL levels at 1500 h, and a 50-fold rise on the morning of day 31. Haloperidol 0-11 prolactin Rattus norvegicus 103-106 2883661-6 1987 These results indicate that acute administration of these SS analogs can induce a prolonged inhibition of PRL release when PRL is acutely elevated by haloperidol or chronically elevated by 3 weeks of estrogen administration. Haloperidol 150-161 prolactin Rattus norvegicus 106-109 2883661-6 1987 These results indicate that acute administration of these SS analogs can induce a prolonged inhibition of PRL release when PRL is acutely elevated by haloperidol or chronically elevated by 3 weeks of estrogen administration. Haloperidol 150-161 prolactin Rattus norvegicus 123-126 2565390-5 1989 GEP (1, 3 and 10 mg/kg) and IPS (10 mg/kg) inhibited the increase in PRL secretion produced by either haloperidol (0.25 mg/kg) or alpha-methyl-p-tyrosine (75 mg/kg). Haloperidol 102-113 prolactin Rattus norvegicus 69-72 2565390-8 1989 Moreover, haloperidol blocked completely the GEP-mediated suppression of PRL secretion in this preparation. Haloperidol 10-21 prolactin Rattus norvegicus 73-76 2565774-4 1989 Isofloxythepin and haloperidol increased concentrations of dihydroxyphenylacetic acid in the striatum and elevated serum prolactin levels. Haloperidol 19-30 prolactin Rattus norvegicus 121-130 2563751-6 1989 Pretreatment with centrally acting dopamine antagonists (spiperone or haloperidol) prevented the (+)-PHNO-induced changes in serum corticosterone, prolactin and brain catecholamines. Haloperidol 70-81 prolactin Rattus norvegicus 147-156 3399028-6 1988 Intracerebroventricular administration of rat prolactin or systemic administration of haloperidol (which increases circulating levels of prolactin) increased DA synthesis in the median eminence of both sham-operated rats and retrochiasmatic-deafferentated rats. Haloperidol 86-97 prolactin Rattus norvegicus 137-146 2883661-0 1987 Inhibitory effects of somatostatin analogs on prolactin secretion in rats pretreated with estrogen or haloperidol. Haloperidol 102-113 prolactin Rattus norvegicus 46-55 2883661-3 1987 When haloperidol was used to elevate PRL level, a single injection of RC-121 inhibited PRL release in EB-pretreated female rats or untreated female and male rats. Haloperidol 5-16 prolactin Rattus norvegicus 37-40 3031276-3 1987 Haloperidol and morphine produced a dose-related stimulation of PRL release in animals of all ages. Haloperidol 0-11 prolactin Rattus norvegicus 64-67 3561698-4 1987 The acute systemic administration of haloperidol, a DA antagonist which increases serum concentrations of prolactin or intracerebroventricular infusions of prolactin increased the rate of dopa accumulation in the median eminence of both young and aged rats by the same relative amount. Haloperidol 37-48 prolactin Rattus norvegicus 106-115 3561698-4 1987 The acute systemic administration of haloperidol, a DA antagonist which increases serum concentrations of prolactin or intracerebroventricular infusions of prolactin increased the rate of dopa accumulation in the median eminence of both young and aged rats by the same relative amount. Haloperidol 37-48 prolactin Rattus norvegicus 156-165 3497800-3 1987 In contrast, chronic treatment of rats with dexamethasone resulted in a potentiation of the PRL response to quipazine, 5-hydroxytryptophan and haloperidol. Haloperidol 143-154 prolactin Rattus norvegicus 92-95 2872066-7 1986 The combined treatment with haloperidol and ID, as above, resulted in an additive effect on hepatic PRL receptors, suggesting that the actions of neuroleptics and ID may be either submaximal or mediated by two different mechanisms. Haloperidol 28-39 prolactin Rattus norvegicus 100-103 3945627-8 1986 Injection of haloperidol (HALO) produced similar increases in plasma PRL/estimated PRL-cell DNA in OVX controls, at the end of E2 treatment or after E2 withdrawal. Haloperidol 13-24 prolactin Rattus norvegicus 69-72 3708389-5 1986 Chronic cysteamine (CYS) treatment decreased body weight gain, acutely decreased cataleptic behavior to HAL, decreased serum rPRL levels, and prevented the increase in serum rPRL levels due to HAL administration. Haloperidol 193-196 prolactin Rattus norvegicus 174-178 3748306-4 1986 However, the sustained intense hyperprolactinemia induced by haloperidol increased the mean PRL level in the CSF and possibly its pulse rate. Haloperidol 61-72 prolactin Rattus norvegicus 92-95 3090463-6 1986 TIDA neurons were very sensitive to changes in circulating concentrations of PRL; their activity was increased if serum PRL concentrations were merely doubled by infusing a low concentration of rPRL for 4 h. Three daily injections of haloperidol elevated circulating rPRL concentrations and increased the rate of DOPA accumulation in the median eminence. Haloperidol 234-245 prolactin Rattus norvegicus 77-80 3090463-6 1986 TIDA neurons were very sensitive to changes in circulating concentrations of PRL; their activity was increased if serum PRL concentrations were merely doubled by infusing a low concentration of rPRL for 4 h. Three daily injections of haloperidol elevated circulating rPRL concentrations and increased the rate of DOPA accumulation in the median eminence. Haloperidol 234-245 prolactin Rattus norvegicus 120-123 3090463-6 1986 TIDA neurons were very sensitive to changes in circulating concentrations of PRL; their activity was increased if serum PRL concentrations were merely doubled by infusing a low concentration of rPRL for 4 h. Three daily injections of haloperidol elevated circulating rPRL concentrations and increased the rate of DOPA accumulation in the median eminence. Haloperidol 234-245 prolactin Rattus norvegicus 194-198 3090463-6 1986 TIDA neurons were very sensitive to changes in circulating concentrations of PRL; their activity was increased if serum PRL concentrations were merely doubled by infusing a low concentration of rPRL for 4 h. Three daily injections of haloperidol elevated circulating rPRL concentrations and increased the rate of DOPA accumulation in the median eminence. Haloperidol 234-245 prolactin Rattus norvegicus 267-271 3945627-8 1986 Injection of haloperidol (HALO) produced similar increases in plasma PRL/estimated PRL-cell DNA in OVX controls, at the end of E2 treatment or after E2 withdrawal. Haloperidol 13-24 prolactin Rattus norvegicus 83-86 3945627-8 1986 Injection of haloperidol (HALO) produced similar increases in plasma PRL/estimated PRL-cell DNA in OVX controls, at the end of E2 treatment or after E2 withdrawal. Haloperidol 26-30 prolactin Rattus norvegicus 69-72 3945627-8 1986 Injection of haloperidol (HALO) produced similar increases in plasma PRL/estimated PRL-cell DNA in OVX controls, at the end of E2 treatment or after E2 withdrawal. Haloperidol 26-30 prolactin Rattus norvegicus 83-86 3840081-6 1985 The stimulatory effects of iv administered domperidone (0.005 or 0.01 mg/rat) and haloperidol (0.2 mg/rat) upon PRL transformation and release in the lactating rat were substantially reduced by cyclo-his-pro in a dose-related fashion over a range of doses from 200-800 ng/min for 5 min. Haloperidol 82-93 prolactin Rattus norvegicus 112-115 3971917-8 1985 The actions of acute and chronically administered haloperidol are reversible, with the reduced DA content of the adenohypophysis and the elevated serum concentrations of PRL returning to respective pretreatment levels in both young and aged rats once treatment stops. Haloperidol 50-61 prolactin Rattus norvegicus 170-173 3987630-4 1985 When PRL levels were increased by pretreatment with alpha-methyl-p-tyrosine or haloperidol, once again both tyramine and dopamine lowered PRL titers. Haloperidol 79-90 prolactin Rattus norvegicus 5-8 4034625-1 1985 Withdrawal from chronic haloperidol exposure was associated to unaltered circulating levels of prolactin (PRL), decreased 3H-spiperone binding sites in the anterior pituitary and increased 3H-spiperone binding sites in the striatum of male rats. Haloperidol 24-35 prolactin Rattus norvegicus 95-104 4034625-1 1985 Withdrawal from chronic haloperidol exposure was associated to unaltered circulating levels of prolactin (PRL), decreased 3H-spiperone binding sites in the anterior pituitary and increased 3H-spiperone binding sites in the striatum of male rats. Haloperidol 24-35 prolactin Rattus norvegicus 106-109 4034625-2 1985 Haloperidol (0.1 mg/kg ip) induced similar rises in plasma PRL in haloperidol-or saline-treated rats and the dose of 0.01 mg/kg was ineffective in both groups. Haloperidol 0-11 prolactin Rattus norvegicus 59-62 3971917-9 1985 The time course for recovery of serum PRL levels and anterior pituitary DA contents after both the acute and chronic haloperidol treatment is of longer duration in the aged rat, which is consistent with a decreased rate of clearance of haloperidol in these animals. Haloperidol 117-128 prolactin Rattus norvegicus 38-41 6527272-0 1984 Effects of benztropine mesylate on haloperidol-induced prolactin secretion and serum haloperidol levels in rats. Haloperidol 35-46 prolactin Rattus norvegicus 55-64 6527272-7 1984 There was a significant correlation (r = 0.57, p less than 0.001) between serum haloperidol levels and serum prolactin levels in haloperidol-treated animals pretreated with either saline or benztropine mesylate. Haloperidol 129-140 prolactin Rattus norvegicus 109-118 3920095-3 1985 Of the treatments examined, estrogen, morphine bromocriptine and haloperidol significantly altered the relationship between Nb2BA and RIA estimates of PRL. Haloperidol 65-76 prolactin Rattus norvegicus 151-154 3883215-1 1985 We investigated the effect of blocking endogenous LH-RH, by injection of anti-LH-RH sera, on serum prolactin levels previously elevated by treatment with haloperidol for 5 days. Haloperidol 154-165 prolactin Rattus norvegicus 99-108 3883215-3 1985 In another group of rats, sheep anti-LH-RH serum induced a significant decrease of serum LH and also lowered serum prolactin levels previously elevated by haloperidol. Haloperidol 155-166 prolactin Rattus norvegicus 115-124 3883215-4 1985 In ovariectomized rats, sheep anti-LH-RH serum markedly reduced serum LH levels and also decreased serum prolactin elevated by the pretreatment with haloperidol. Haloperidol 149-160 prolactin Rattus norvegicus 105-114 3883215-5 1985 It is concluded that the blocking of endogenous LH-RH action results in a decreased release of prolactin in response to stimuli like haloperidol. Haloperidol 133-144 prolactin Rattus norvegicus 95-104 6527272-1 1984 The effects of benztropine mesylate on haloperidol-induced prolactin secretion and serum haloperidol levels were investigated in 240 rats. Haloperidol 39-50 prolactin Rattus norvegicus 59-68 6527272-5 1984 Haloperidol caused a significant rise (p less than 0.0001) in serum prolactin compared with controls. Haloperidol 0-11 prolactin Rattus norvegicus 68-77 6527272-6 1984 The prolactin concentration for the 30-150-min sampling period was significantly higher when the rats received benztropine mesylate prior to haloperidol (p less than 0.05). Haloperidol 141-152 prolactin Rattus norvegicus 4-13 6527272-7 1984 There was a significant correlation (r = 0.57, p less than 0.001) between serum haloperidol levels and serum prolactin levels in haloperidol-treated animals pretreated with either saline or benztropine mesylate. Haloperidol 80-91 prolactin Rattus norvegicus 109-118 6685809-3 1983 However, trazodone could not be considered to be a potent stimulator of prolactin secretion, since the injection of haloperidol at 2 mg/kg elevated serum prolactin to values twice those seen in animals receiving the 80 mg/kg dose of trazodone. Haloperidol 116-127 prolactin Rattus norvegicus 154-163 6423371-8 1984 Of two antidopaminergic drugs, haloperidol and l-sulpiride, only the first inhibited the release of PRL at high doses (10(-5) - 10(-4) M) in the presence of sodium but became stimulatory at 10(-4) M in the absence of the ion. Haloperidol 31-42 prolactin Rattus norvegicus 100-103 6745164-4 1984 Drugs that decrease DA in the hypophysial portal blood (alpha-methyltyrosine, gamma-butyrolactone, and reserpine) or block DA receptors (haloperidol) increased PRL secretion and decreased DA content and lysosomal enzyme activity. Haloperidol 137-148 prolactin Rattus norvegicus 160-163 6426788-5 1984 Sham-operated intact rats and bilaterally ovariectomized rats were given daily injections of haloperidol to increase prolactin secretion, bromocryptine to decrease prolactin secretion, and/or estradiol benzoate (EB). Haloperidol 93-104 prolactin Rattus norvegicus 117-126 6326446-6 1984 Pre-treatment of intact animals with the catecholamine receptor blocking agent haloperidol (1.0 mg/kg at 13.00 h) resulted in a further elevation of plasma Prl levels as compared with untreated controls, but eliminated the decrease of Prl in response to restraint stress. Haloperidol 79-90 prolactin Rattus norvegicus 156-159 6326446-6 1984 Pre-treatment of intact animals with the catecholamine receptor blocking agent haloperidol (1.0 mg/kg at 13.00 h) resulted in a further elevation of plasma Prl levels as compared with untreated controls, but eliminated the decrease of Prl in response to restraint stress. Haloperidol 79-90 prolactin Rattus norvegicus 235-238 6315179-0 1983 Influence of sex steroids and prolactin on haloperidol-induced catalepsy. Haloperidol 43-54 prolactin Rattus norvegicus 30-39 6642209-10 1983 3 days after Hal withdrawal, baseline PRL levels were significantly higher in aged Hal-treated rats than in vehicle-injected or young Hal-treated rats and so were pituitary concentrations of PRL. Haloperidol 83-86 prolactin Rattus norvegicus 38-41 6642209-2 1983 In addition, PRL responsiveness to acute or repeated administration of haloperidol (Hal), a DA receptor antagonist, was assessed in either young or old rats. Haloperidol 71-82 prolactin Rattus norvegicus 13-16 6642209-2 1983 In addition, PRL responsiveness to acute or repeated administration of haloperidol (Hal), a DA receptor antagonist, was assessed in either young or old rats. Haloperidol 84-87 prolactin Rattus norvegicus 13-16 6642209-9 1983 In aged rats treated chronically with Hal (0.5 mg/kg i.p., twice daily for 14 days) and sampled at the 8th day, 1 h after the first daily Hal injection, plasma PRL rose to levels about 3-fold as high as those after the first injection; in young rats, instead, the PRL-releasing effect of Hal was similar to that evoked by the first administration. Haloperidol 38-41 prolactin Rattus norvegicus 160-163 6642209-9 1983 In aged rats treated chronically with Hal (0.5 mg/kg i.p., twice daily for 14 days) and sampled at the 8th day, 1 h after the first daily Hal injection, plasma PRL rose to levels about 3-fold as high as those after the first injection; in young rats, instead, the PRL-releasing effect of Hal was similar to that evoked by the first administration. Haloperidol 38-41 prolactin Rattus norvegicus 264-267 6642209-10 1983 3 days after Hal withdrawal, baseline PRL levels were significantly higher in aged Hal-treated rats than in vehicle-injected or young Hal-treated rats and so were pituitary concentrations of PRL. Haloperidol 83-86 prolactin Rattus norvegicus 38-41 6642209-10 1983 3 days after Hal withdrawal, baseline PRL levels were significantly higher in aged Hal-treated rats than in vehicle-injected or young Hal-treated rats and so were pituitary concentrations of PRL. Haloperidol 83-86 prolactin Rattus norvegicus 191-194 6642209-10 1983 3 days after Hal withdrawal, baseline PRL levels were significantly higher in aged Hal-treated rats than in vehicle-injected or young Hal-treated rats and so were pituitary concentrations of PRL. Haloperidol 83-86 prolactin Rattus norvegicus 191-194 6291923-6 1983 Penfluridol, pimozide, and haloperidol inhibited basal PRL secretion in a dose-related manner, with the EC50 ranging from 0.5-1 microM for penfluridol to 1-2 microM for pimozide and more than 3 microM for haloperidol. Haloperidol 27-38 prolactin Rattus norvegicus 55-58 6616203-3 1983 At intervals longer than 30 min, 5-MeODMT (1-15 mg/kg) inhibits the stimulation of PRL secretion by another 5-HT agonist, 5-methoxytryptamine (5-MeOT, 10 mg/kg), by alpha-methylparatyrosine (50 mg/kg) or by haloperidol (0.15 mg/kg). Haloperidol 207-218 prolactin Rattus norvegicus 83-86 6131816-15 1983 Injection of the DA antagonist, haloperidol, to adult rats resulted in a significant elevation of plasma PRL and in a significant reduction of ER concentration in the AP. Haloperidol 32-43 prolactin Rattus norvegicus 105-108 6860978-0 1983 Prolactin increases the activity of tuberoinfundibular and nigroneostriatal dopamine neurons: prolactin antiserum inhibits the haloperidol-induced increases in dopamine synthesis rates in median eminence and striatum of rats. Haloperidol 127-138 prolactin Rattus norvegicus 0-9 6860978-0 1983 Prolactin increases the activity of tuberoinfundibular and nigroneostriatal dopamine neurons: prolactin antiserum inhibits the haloperidol-induced increases in dopamine synthesis rates in median eminence and striatum of rats. Haloperidol 127-138 prolactin Rattus norvegicus 94-103 6860978-1 1983 The role of PRL in mediating the haloperidol-induced increase in tuberoinfundibular dopamine synthesis rate was assessed by studying the effects of administration of PRL antiserum. Haloperidol 33-44 prolactin Rattus norvegicus 12-15 6828202-1 1983 Haloperidol, sulpiride, domperidone and apomorphine, drugs which influence dopamine (DA) receptors and in turn prolactin (PRL) secretion have been shown to induce parallel changes in medial basal hypothalamic (MBH) glutamate decarboxylase (GAD) activity and serum PRL levels. Haloperidol 0-11 prolactin Rattus norvegicus 122-125 6828202-1 1983 Haloperidol, sulpiride, domperidone and apomorphine, drugs which influence dopamine (DA) receptors and in turn prolactin (PRL) secretion have been shown to induce parallel changes in medial basal hypothalamic (MBH) glutamate decarboxylase (GAD) activity and serum PRL levels. Haloperidol 0-11 prolactin Rattus norvegicus 264-267 6856617-1 1983 The purpose of this study was to determine whether administration of estrogen or/and haloperidol (HAL), a drug that increases prolactin (PRL) secretion, could counteract the inhibitory effects of underfeeding on growth of established carcinogen-induced mammary cancers in rats. Haloperidol 85-96 prolactin Rattus norvegicus 126-135 6856617-1 1983 The purpose of this study was to determine whether administration of estrogen or/and haloperidol (HAL), a drug that increases prolactin (PRL) secretion, could counteract the inhibitory effects of underfeeding on growth of established carcinogen-induced mammary cancers in rats. Haloperidol 85-96 prolactin Rattus norvegicus 137-140 6856617-1 1983 The purpose of this study was to determine whether administration of estrogen or/and haloperidol (HAL), a drug that increases prolactin (PRL) secretion, could counteract the inhibitory effects of underfeeding on growth of established carcinogen-induced mammary cancers in rats. Haloperidol 98-101 prolactin Rattus norvegicus 126-135 6856617-1 1983 The purpose of this study was to determine whether administration of estrogen or/and haloperidol (HAL), a drug that increases prolactin (PRL) secretion, could counteract the inhibitory effects of underfeeding on growth of established carcinogen-induced mammary cancers in rats. Haloperidol 98-101 prolactin Rattus norvegicus 137-140 6860978-5 1983 Haloperidol increased median eminence dopamine synthesis rate, and PRL antiserum completely prevented this effect, supporting the thesis that the haloperidol-induced increase in tuberoinfundibular dopamine turnover is mediated by PRL. Haloperidol 146-157 prolactin Rattus norvegicus 67-70 6860978-5 1983 Haloperidol increased median eminence dopamine synthesis rate, and PRL antiserum completely prevented this effect, supporting the thesis that the haloperidol-induced increase in tuberoinfundibular dopamine turnover is mediated by PRL. Haloperidol 146-157 prolactin Rattus norvegicus 230-233 6860978-7 1983 In addition to its effect in median eminence, PRL antiserum blunted the haloperidol-induced increase in striatal dopamine synthesis rate, suggesting that the haloperidol-induced increase in nigroneostriatal dopamine turnover is mediated in part by PRL. Haloperidol 72-83 prolactin Rattus norvegicus 46-49 6860978-7 1983 In addition to its effect in median eminence, PRL antiserum blunted the haloperidol-induced increase in striatal dopamine synthesis rate, suggesting that the haloperidol-induced increase in nigroneostriatal dopamine turnover is mediated in part by PRL. Haloperidol 72-83 prolactin Rattus norvegicus 248-251 6860978-7 1983 In addition to its effect in median eminence, PRL antiserum blunted the haloperidol-induced increase in striatal dopamine synthesis rate, suggesting that the haloperidol-induced increase in nigroneostriatal dopamine turnover is mediated in part by PRL. Haloperidol 158-169 prolactin Rattus norvegicus 46-49 6860978-7 1983 In addition to its effect in median eminence, PRL antiserum blunted the haloperidol-induced increase in striatal dopamine synthesis rate, suggesting that the haloperidol-induced increase in nigroneostriatal dopamine turnover is mediated in part by PRL. Haloperidol 158-169 prolactin Rattus norvegicus 248-251 6291923-6 1983 Penfluridol, pimozide, and haloperidol inhibited basal PRL secretion in a dose-related manner, with the EC50 ranging from 0.5-1 microM for penfluridol to 1-2 microM for pimozide and more than 3 microM for haloperidol. Haloperidol 205-216 prolactin Rattus norvegicus 55-58 7100626-1 1982 Haloperidol, in concentrations in excess of 10(-5)M promotes the release of prolactin from rat anterior pituitary cells in monolayer culture. Haloperidol 0-11 prolactin Rattus norvegicus 76-85 6811103-3 1982 Five days after the last injection of haloperidol, animals pretreated with haloperidol showed a significantly longer lasting inhibition of prolactin (PRL) secretion by apomorphine, compared with the controls. Haloperidol 75-86 prolactin Rattus norvegicus 139-148 7100626-3 1982 Paradoxically, at 10(-5)M, haloperidol significantly inhibited prolactin release and promoted an accumulation of intracellular secretory granules. Haloperidol 27-38 prolactin Rattus norvegicus 63-72 7100626-5 1982 Although it is nominally classified as a dopamine receptor blocker and can (in lower concentrations) inhibit dopamine"s suppression of prolactin release, haloperidol in higher concentration enhances prolactin release by a cytotoxic mechanism unrelated to dopamine receptor interaction. Haloperidol 154-165 prolactin Rattus norvegicus 199-208 7070218-3 1982 These results suggest that prolactin might be the common mediator of the increase in striatal DA receptor density produced by either estrogen or haloperidol administration. Haloperidol 145-156 prolactin Rattus norvegicus 27-36 7068107-1 1982 The administration of haloperidol increased serum prolactin and decreased the pituitary concentration of prolactin 15 min after its administration. Haloperidol 22-33 prolactin Rattus norvegicus 50-59 7068107-1 1982 The administration of haloperidol increased serum prolactin and decreased the pituitary concentration of prolactin 15 min after its administration. Haloperidol 22-33 prolactin Rattus norvegicus 105-114 7266775-3 1981 Haloperidol and pimozide increased serum prolactin levels. Haloperidol 0-11 prolactin Rattus norvegicus 41-50 6269703-3 1981 However, lithium treatment apparently potentiated PRL release by haloperidol in both conscious and urethane-anesthetized rats. Haloperidol 65-76 prolactin Rattus norvegicus 50-53 6979001-4 1982 Diazepam administration also blunted the release of prolactin induced by dopaminergic receptor blockade following haloperidol, or by serotonergic receptor activation produced by fluoxetine, a serotonergic reuptake inhibitor plus 5-hydroxytryptophan, a serotonin precursor. Haloperidol 114-125 prolactin Rattus norvegicus 52-61 7266775-4 1981 Pituitary prolactin concentrations fell 12h after haloperidol, recovering b6 24h, and 24 and 48h after pimozide, recovering by 72 h. Bromocriptine lowered pituitary DNA synthesis and serum prolactin levels and induced a transient rise in pituitary prolactin concentrations. Haloperidol 50-61 prolactin Rattus norvegicus 10-19 7371016-4 1980 Dexamethasone produced significant regression of mammary tumors and reduced serum prolactin levels, whereas haloperidol significantly increased mammary tumor growth and greatly elevated serum prolactin levels. Haloperidol 108-119 prolactin Rattus norvegicus 192-201 6104725-3 1980 Dose-response curves indicated the following order of prolactin stimulating potency: haloperidol greater than reduced haloperidol congruent to lenperone greater than chlorpromazine greater than AHR-1900 greater than thioridazine greater than clozapine greater than U-25927 greater than SCH-12679. Haloperidol 85-96 prolactin Rattus norvegicus 54-63 6104725-3 1980 Dose-response curves indicated the following order of prolactin stimulating potency: haloperidol greater than reduced haloperidol congruent to lenperone greater than chlorpromazine greater than AHR-1900 greater than thioridazine greater than clozapine greater than U-25927 greater than SCH-12679. Haloperidol 118-129 prolactin Rattus norvegicus 54-63 6104725-7 1980 Reduced haloperidol, a major metabolite of haloperidol, was one-fourth as potent as haloperidol in stimulating prolactin release, suggesting that the potential antipsychotic activity of reduced haloperidol should be investigated. Haloperidol 8-19 prolactin Rattus norvegicus 111-120 7238586-3 1981 Conversely, a return to normal of the GAD activity associated with high plasma PRL levels was induced by chronic haloperidol and sulpiride treatment. Haloperidol 113-124 prolactin Rattus norvegicus 79-82 7371016-5 1980 When dexamethasone and haloperidol were injected together, there was significant regression of mammary tumors despite markedly elevated serum prolactin levels. Haloperidol 23-34 prolactin Rattus norvegicus 142-151 7371016-7 1980 These results indicate that dexamethasone, a synthetic glucocorticoid, can directly inhibit mammary tumor growth in the presence of elevated serum prolactin levels produced by haloperidol, and this inhibition is not due to a reduction of prolactin binding sites in the tumor tissue. Haloperidol 176-187 prolactin Rattus norvegicus 147-156 7379927-1 1980 Oral administration of 2 neuroleptic drugs, haloperidol and LR511 induced in male rats a marked, dose-dependent and sustained rise of plasma prolactin. Haloperidol 44-55 prolactin Rattus norvegicus 141-150 7353525-3 1980 The haloperidol-induced increase in the concentration of dopamine in pituitary stalk plasma appeared to be PRL mediated, since this effect of haloperidol was significantly attenuated in rats which had been pretreated with antiserum to PRL. Haloperidol 4-15 prolactin Rattus norvegicus 107-110 7353525-3 1980 The haloperidol-induced increase in the concentration of dopamine in pituitary stalk plasma appeared to be PRL mediated, since this effect of haloperidol was significantly attenuated in rats which had been pretreated with antiserum to PRL. Haloperidol 4-15 prolactin Rattus norvegicus 235-238 7353525-3 1980 The haloperidol-induced increase in the concentration of dopamine in pituitary stalk plasma appeared to be PRL mediated, since this effect of haloperidol was significantly attenuated in rats which had been pretreated with antiserum to PRL. Haloperidol 142-153 prolactin Rattus norvegicus 107-110 7353525-3 1980 The haloperidol-induced increase in the concentration of dopamine in pituitary stalk plasma appeared to be PRL mediated, since this effect of haloperidol was significantly attenuated in rats which had been pretreated with antiserum to PRL. Haloperidol 142-153 prolactin Rattus norvegicus 235-238 436760-5 1979 Haloperidol (10 microM) inhibited PRL release to 23% of control values and did not affect GH release; 3.3 microM pimozide inhibited PRL and GH release to 18% and 38% of control values, respectively. Haloperidol 0-11 prolactin Rattus norvegicus 34-37 6110459-0 1980 Chlorpromazine, haloperidol, metoclopramide and domperidone release prolactin through dopamine antagonism at low concentrations but paradoxically inhibit prolactin release at high concentrations. Haloperidol 16-27 prolactin Rattus norvegicus 68-77 6110459-0 1980 Chlorpromazine, haloperidol, metoclopramide and domperidone release prolactin through dopamine antagonism at low concentrations but paradoxically inhibit prolactin release at high concentrations. Haloperidol 16-27 prolactin Rattus norvegicus 154-163 6110459-4 1980 Chlorpromazine, haloperidol, metoclopramide and domperidone antagonized the dopamine-mediated inhibition of prolactin release at low concentrations. Haloperidol 16-27 prolactin Rattus norvegicus 108-117 6110459-10 1980 At high concentrations in the absence of dopamine, chlorpromazine, haloperidol, metoclopramide and domperidone paradoxically suppressed prolactin secretion by an unknown mechanism. Haloperidol 67-78 prolactin Rattus norvegicus 136-145 503252-4 1979 The stimulation of prolactin release by morphine and its reversal by pilocarpine were observed after the administration of haloperidol or alpha-methyltyrosine. Haloperidol 123-134 prolactin Rattus norvegicus 19-28 288372-2 1979 In rats, all functional dopamine antagonists (reserpine alone or combined with alpha-methyl-p-tyrosine or benserazide, haloperidol, spiroperidol, sulpiride) increased serum PRL levels. Haloperidol 119-130 prolactin Rattus norvegicus 173-176 745306-3 1978 The increase in the serum PRL levels by haloperidol was abolished by apomorphine, but not by naloxone. Haloperidol 40-51 prolactin Rattus norvegicus 26-29 745306-6 1978 Although neither haloperidol nor morphine increased the release of PRL from the isolated anterior pituitary, haloperidol, but not morphine, reversed the inhibition by dopamine of the in vitro release of pituitary PRL. Haloperidol 109-120 prolactin Rattus norvegicus 213-216 25696-4 1978 Furthermore, the administration of haloperidol to hypophysectomized rats also significantly increased the TH activity in the ME, indicating that such changes may occur independently of any changes in serum prolactin levels. Haloperidol 35-46 prolactin Rattus norvegicus 206-215 641429-2 1978 Haloperidol increased serum prolactin but did not stimulate pituitary DNA synthesis or reduce pituitary prolactin concentrations. Haloperidol 0-11 prolactin Rattus norvegicus 28-37 641429-3 1978 Haloperidol potentiated the effects of oestrogen on serum prolactin and on pituitary DNA synthesis; pituitary prolactin concentrations were greatly reduced, and growth hormone secretion was slightly inhibited. Haloperidol 0-11 prolactin Rattus norvegicus 58-67 641429-5 1978 Haloperidol, given to rats treated with oestrogen and bromocriptine, reversed the inhibitory effects of bromocriptine on DNA synthesis and serum prolactin; pituitary prolactin concentrations fell to well below normal. Haloperidol 0-11 prolactin Rattus norvegicus 145-154 641429-5 1978 Haloperidol, given to rats treated with oestrogen and bromocriptine, reversed the inhibitory effects of bromocriptine on DNA synthesis and serum prolactin; pituitary prolactin concentrations fell to well below normal. Haloperidol 0-11 prolactin Rattus norvegicus 166-175 641429-6 1978 The results suggest that the haloperidol potentiation of oestrogen-induced pituitary DNA synthesis may depend upon stimulation of prolactin secretion together with reduction of intracellular prolactin levels. Haloperidol 29-40 prolactin Rattus norvegicus 130-139 641429-6 1978 The results suggest that the haloperidol potentiation of oestrogen-induced pituitary DNA synthesis may depend upon stimulation of prolactin secretion together with reduction of intracellular prolactin levels. Haloperidol 29-40 prolactin Rattus norvegicus 191-200 690628-0 1978 Localization of the site of the haloperidol-induced, prolactin-mediated increase of dopamine turnover in the median eminence: studies in rats with complete hypothalamic deafferentations. Haloperidol 32-43 prolactin Rattus norvegicus 53-62 690628-4 1978 Basal serum prolactin concentrations were unaltered in these rats but were elevated 16 hours after the injection of haloperidol and 1 hour after alpha-methyltyrosine. Haloperidol 116-127 prolactin Rattus norvegicus 12-21 690628-6 1978 These results indicate that the haloperidol-induced, prolactin-mediated increase of dopamine turnover in the median eminence results from a direct action of this hormone on neurons within the medial basal hypothalamus. Haloperidol 32-43 prolactin Rattus norvegicus 53-62 958594-0 1976 Differential effects of dopamine agonists and haloperidol on release of prolactin, thyroid stimulating hormone, growth hormone and luteinizing hormone in rats. Haloperidol 46-57 prolactin Rattus norvegicus 72-81 912401-1 1977 Rats treated with haloperidol or bearing subcutaneous implants of prolactin-secreting tumors had elevated CSF prolactin levels compared to those observed in control rats. Haloperidol 18-29 prolactin Rattus norvegicus 66-75 912401-1 1977 Rats treated with haloperidol or bearing subcutaneous implants of prolactin-secreting tumors had elevated CSF prolactin levels compared to those observed in control rats. Haloperidol 18-29 prolactin Rattus norvegicus 110-119 909609-13 1977 A good correlation was found between the haloperidol concentration in the brain on the one hand and its effects on behaviour, on serum prolactin values and on Dopa formation on the other. Haloperidol 41-52 prolactin Rattus norvegicus 135-144 954668-2 1976 In male rats treated with reserpine, chlorpromazine, haloperidol, or pimozide, serum prolactin levels were greatly elevated. Haloperidol 53-64 prolactin Rattus norvegicus 85-94 958594-1 1976 The dose-response effects of apomorphine and ET-495 (piribedil), 2 specific dopamine (DA) receptor stimulators, and haloperidol, a DA receptor blocker, were tested on the secretion of prolactin (PRL), thyroid stimulating hormone (TSH), growth hormone (GH) and luteinizing hormone (LH) in male rats. Haloperidol 116-127 prolactin Rattus norvegicus 184-193 958594-7 1976 Administration of haloperidol elevated serum PRL, tended to lower TSH, dramatically reduced GH and had no effect on LH levels. Haloperidol 18-29 prolactin Rattus norvegicus 45-48 958594-8 1976 Haloperidol pre-treatment blocked the effects of apomorphine on PRL, TSH, and GH secretion. Haloperidol 0-11 prolactin Rattus norvegicus 64-67